Latest Litigation News

Classic Minerals Limited has issued a prospectus for a nominal share offer aimed at removing trading restrictions on placement shares issued to creditors, while navigating significant financial challenges and ongoing litigation over key tenements.

Mayne Pharma disputes Cosette Pharmaceuticals’ attempt to terminate their acquisition agreement, with a key court hearing postponed to September and a crucial shareholder vote set for June 18.

Titan Minerals Limited has launched a transaction-specific prospectus offering 4 million new options to its underwriter, exercisable at A$0.70 and expiring in January 2027. The offer, which raises no immediate funds, could inject approximately A$2.8 million upon option exercise.

QuickFee Limited has launched a A$1.5 million capital raising to fund expansion of its loan books in the US and Australia, following a quarter of record revenue and positive earnings before tax. The fintech also completed a major refinancing and revised its earnings guidance due to a credit impairment provision.

Ovanti Limited is set to raise approximately $1 million through a two-tranche share placement to support its US buy now, pay later expansion and ongoing legal matters.

Mayne Pharma rebuffs Cosette's claim of a material adverse change in their merger scheme and secures FDA clearance on regulatory concerns, maintaining its commitment to the deal's completion.

Fintech Chain Limited reported a 24% revenue increase to RMB55.9 million for FY2025 driven by new SaaS products, yet it remains in the red with a net loss of RMB4.8 million. The company has also applied for delisting from the ASX.

Lord Resources Limited has announced a pro-rata non-renounceable entitlement issue to raise approximately $1.39 million, primarily to fund exploration at its Ilgarari Copper Project. The offer presents both opportunity and risk for shareholders amid ongoing funding needs and exploration uncertainties.

ALS Limited has announced a fully underwritten A$350 million equity placement to fund major upgrades to its global laboratory network and support future growth initiatives, aiming for mid single-digit EPS accretion by FY25 pro forma.

London City reports a record investment portfolio value of $27.3 million, buoyed by strong gains in Fiducian Group shares, while legal proceedings against Excelsior Capital and its directors continue to unfold.

Mayne Pharma has firmly rejected Cosette Pharmaceuticals’ assertion of a Material Adverse Change that could derail their acquisition scheme, insisting the deal process continues as planned.

Mayne Pharma Group has proposed a $7.40 per share acquisition by Cosette Pharmaceuticals, with unanimous board support and a fair and reasonable opinion from an independent expert. Shareholders will vote on the scheme on June 18, 2025.